Takeda Pharmaceutical Co. $TAK Stock: Ethic Inc. Increases Stake

Key Points

• Ethic Inc. increased its Takeda stake by 19.5% in the third quarter, adding 71,261 shares to hold 436,514 shares valued at about $7.94 million. Several other institutions also increased or initiated positions; institutions own 9.17% of the stock.
• Takeda shares opened at $21.02, near their 52-week high of $21.73. The stock has a consensus Buy rating from analysts cited in the article.
• Company insiders sold 238,974 shares worth about $4.55 million over the past 90 days; insiders retain 0.04% ownership.

Ethic Inc. raised its position in shares of Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 19.5% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 436,514 shares of the company's stock after buying an additional 71,261 shares during the quarter. Ethic Inc.'s holdings in Takeda Pharmaceutical were worth $7,940,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. May Hill Capital LLC bought a new position in shares of Takeda Pharmaceutical during the 3rd quarter worth approximately $256,000. Commonwealth Equity Services LLC boosted its stake in Takeda Pharmaceutical by 20.7% in the third quarter. Commonwealth Equity Services LLC now owns 27,282 shares of the company's stock valued at $496,000 after acquiring an additional 4,684 shares in the last quarter. Ascent Group LLC boosted its stake in Takeda Pharmaceutical by 19.5% in the third quarter. Ascent Group LLC now owns 19,996 shares of the company's stock valued at $364,000 after acquiring an additional 3,262 shares in the last quarter. Pzena Investment Management LLC boosted its stake in Takeda Pharmaceutical by 19.8% in the third quarter. Pzena Investment Management LLC now owns 45,310 shares of the company's stock valued at $824,000 after acquiring an additional 7,490 shares in the last quarter. Finally, Provenance Wealth Advisors LLC purchased a new position in Takeda Pharmaceutical in the third quarter worth $27,000. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Stock Performance

TAK opened at $21.02 on Monday. Takeda Pharmaceutical Co. has a 52-week low of $13.56 and a 52-week high of $21.73. The company has a quick ratio of 0.60, a current ratio of 1.15 and a debt-to-equity ratio of 0.56. The company has a market cap of $67.35 billion, a P/E ratio of 27.65 and a beta of -0.02. The firm's 50-day moving average price is $19.12 and its 200-day moving average price is $17.67.

Insider Activity at Takeda Pharmaceutical

In other Takeda Pharmaceutical news, insider Andrew Plump sold 116,191 shares of the business's stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $18.49, for a total transaction of $2,148,371.59. Following the sale, the insider owned 145,465 shares of the company's stock, valued at approximately $2,689,647.85. The trade was a 44.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Deidre Greenway sold 12,980 shares of the company's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $18.11, for a total transaction of $235,067.80. Following the transaction, the insider owned 40,049 shares in the company, valued at $725,287.39. The trade was a 24.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 238,974 shares of company stock valued at $4,549,461 over the last 90 days. Company insiders own 0.04% of the company's stock.

Analysts Set New Price Targets

TAK has been the topic of a number of recent analyst reports. Wall Street Zen raised Takeda Pharmaceutical from a "hold" rating to a "buy" rating in a research report on Saturday, July 18th. Weiss Ratings upgraded Takeda Pharmaceutical from a "hold (c)" rating to a "hold (c+)" rating in a report on Tuesday, November 3rd. Finally, Zacks Research raised Takeda Pharmaceutical from a "hold" rating to a "strong-buy" rating in a research report on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Takeda Pharmaceutical presently has a consensus rating of "Buy".

About Takeda Pharmaceutical

Takeda Pharmaceutical Company is a Japan-based global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Founded in Osaka in 1781 as a medicine wholesaler, it has grown into an international pharmaceutical business headquartered in Tokyo.

The company focuses on gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments for conditions such as inflammatory bowel disease and hereditary angioedema, along with medicines and vaccines across its other therapeutic areas.

Takeda serves patients and healthcare providers in Japan and markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.